Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CML-SCT - IBFM Study
2008-000569-50Phase 2Terminated
- Sponsor
- St. Anna Children's Cancer Research Institute
- Start
- Feb 2009
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thiotepa, melphalan and fludarabine in chronic myelogenous leukemia (CML), sponsored by St. Anna Children's Cancer Research Institute. Primary endpoint: transplant related mortality. Started Feb 2009; status: terminated.
02
Drugs
thiotepamelphalanfludarabine
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2008-000569-50.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000569-50.